2016 PREVIEW: South Korea - License Deals, Biosimilar Approvals In Store
This article was originally published in PharmAsia News
South Korea’s pharma/biotech industry is set for another active year for licensing deals and partnerships, while the government is expected to step up support for the development of new innovative therapies and introduce a new law concerning regenerative medicines. PharmAsia News takes a look at some of the likely key events in the country’s corporate and regulatory sectors this year.
Register for our free email digests: